Kết quả tìm kiếm - Mark-David Levin
- Đang hiển thị 1 - 20 kết quả của 39
- Chuyển đến trang tiếp theo
-
1
-
2
-
3
-
4
-
5
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice Bằng Nathalie I. Bouwer, Agnes Jager, Crista Liesting, Marcel J.M. Kofflard, Jasper J. Brugts, Jos Kitzen, Eric Boersma, Mark‐David Levin
Được phát hành 2020Revisão -
6
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients Bằng Paul J. Hengeveld, Joyce Schilperoord‐Vermeulen, P. Martijn Kolijn, Julie Dubois, Peter E. Westerweel, Sabina Kersting, Arnon P. Kater, Mark‐David Levin, Anton W. Langerak
Được phát hành 2025Carta -
7
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019 Bằng Lina van der Straten, Mark‐David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed
Được phát hành 2023Artigo -
8
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study Bằng Marinus H. J. van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, Mario Petrini, Fritz Offner, Sebastian Grosicki, Mark-David Levin, Ira Gupta, Jennifer L. Phillips, Vanessa C. Williams, Stephanie Manson, Steen Lisby, Christian H. Geisler
Được phát hành 2015Artigo -
9
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia Bằng Iris de Weerdt, Roeland Lameris, Jurjen M. Ruben, Renate de Boer, Jan Kloosterman, Lisa A. King, Mark‐David Levin, Paul W.H.I. Parren, Tanja D. de Gruijl, Arnon P. Kater, Hans van Vliet
Được phát hành 2021Artigo -
10
Efficacy and safety of daratumumab combined with all-<i>trans</i>retinoic acid in relapsed/refractory multiple myeloma Bằng Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Tuna Mutis, Christie P.M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W.C.J. van de Donk
Được phát hành 2021Artigo -
11
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial Bằng Pieter Sonneveld, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, Markus Munder, María‐Victoria Mateos, Tomer M. Mark, Mark‐David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer
Được phát hành 2022Artigo -
12
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (... Bằng Philippe Moreau, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Façon, Xavier Leleu, Karim Belhadj, Lionel Karlin, Lotfi Benboubker, Mark‐David Levin, Monique C. Minnema, Bastien Jamet, Caroline Bodet‐Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Françoise Kraeber‐Bodéré
Được phát hành 2019Artigo -
13
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation Bằng Paul G. Kemps, Konnie M. Hebeda, Steven T. Pals, Robert M. Verdijk, King H. Lam, Annette H. Bruggink, Heleen S de Lil, Bart Ruiterkamp, Koen de Heer, Jan AM van Laar, Peter J.M. Valk, Pim Mutsaers, Mark‐David Levin, Pancras C.W. Hogendoorn, Astrid G. S. van Halteren
Được phát hành 2020Artigo -
14
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy Bằng Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark‐David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt
Được phát hành 2019Artigo -
15
COVID-19 vaccination in patients with immune thrombocytopenia Bằng Chantal Visser, Maurice Swinkels, Erik van Werkhoven, F. Nanne Croles, H. S. Noordzij-Nooteboom, Matthijs Eefting, Suzanne Last-Koopmans, Cecile Idink, Peter E. Westerweel, Bart Santbergen, Pieter A. Jobse, Fazil Baboe, Peter te Boekhorst, Frank W.G. Leebeek, Mark‐David Levin, Marieke J. H. A. Kruip, A.J. Gerard Jansen
Được phát hành 2021Artigo -
16
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment Bằng Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B. M. Remmerswaal, Fréderike J. Bemelman, Carsten Utoft Niemann, Sabina Kersting, Mark‐David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Được phát hành 2019Artigo -
17
First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study Bằng Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Qianya Qi, Emma A. Elliott Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Được phát hành 2023Artigo -
18
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib Bằng Iris de Weerdt, Tom Hofland, Roeland Lameris, Sanne Endstra, Aldo Jongejan, Perry D. Moerland, Renée C.G. de Bruin, Ester B. M. Remmerswaal, Ineke J. M. ten Berge, Nora Liu, Mario van der Stelt, Laura M. Faber, Mark‐David Levin, Eric Eldering, Sanne H. Tonino, Tanja D. de Gruijl, Hans van Vliet, Arnon P. Kater
Được phát hành 2018Artigo -
19
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analys... Bằng Arnon P. Kater, Mark‐David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, G.J. Veldhuis, Rogier Mous, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Johan A. Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Carsten Utoft Niemann
Được phát hành 2022Artigo -
20
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study Bằng Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Don A. Stevens, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Được phát hành 2023Artigo
Công cụ tìm kiếm:
Các môn học liên quan
Medicine
Internal medicine
Oncology
Chronic lymphocytic leukemia
Leukemia
Multiple myeloma
Immunology
Chemotherapy
Biology
Daratumumab
Surgery
Gastroenterology
Lenalidomide
Cancer research
Venetoclax
Bortezomib
Cancer
Confidence interval
Dexamethasone
Immune system
Thalidomide
Disease
Environmental health
Physics
Population
Refractory (planetary science)
Astrobiology
Biochemistry
Clinical endpoint
Clinical trial